From the Guidelines
Nasacort should not be used twice daily (BID) as the recommended dosing is once daily. According to the clinical practice guideline for allergic rhinitis 1, the recommended dose for Nasacort (triamcinolone acetonide) is 1-2 sprays per nostril every day for adults and children 12 years and older, and 1 spray per nostril every day for children 2-11 years old.
Key Points to Consider
- The standard dosing for Nasacort is once daily, with a total daily dose of 110-220 mcg for adults and children 12 years and older, and 55 mcg for children 2-11 years old.
- Using Nasacort more frequently than recommended does not provide additional benefit and may increase the risk of side effects such as pharyngitis, epistaxis, and cough 1.
- Nasacort works by reducing inflammation in the nasal passages, which helps relieve symptoms of allergic rhinitis like sneezing, itching, and runny nose.
- The medication builds up its effect over time, so consistent daily use as directed is more effective than using it intermittently or at a higher frequency than recommended.
Important Considerations
- It is essential to follow the recommended dosing to minimize the risk of side effects and maximize the effectiveness of the medication.
- Patients should be advised to use Nasacort consistently and as directed to achieve optimal results.
- If symptoms persist or worsen, patients should consult their healthcare provider for further evaluation and guidance.
From the Research
Nasacort BID
- Nasacort, also known as triamcinolone acetonide, is an intranasal corticosteroid used to treat allergic rhinitis 2, 3, 4, 5.
- The typical dosage of Nasacort is 1-2 sprays per nostril once daily, but the specific dosage and frequency may vary depending on the patient's condition and response to treatment 3, 4.
- Studies have shown that intranasal corticosteroids like Nasacort are effective in relieving symptoms of allergic rhinitis, including nasal congestion, itching, rhinorrhea, and sneezing 2, 3, 6.
- Nasacort has been compared to other intranasal corticosteroids, such as fluticasone propionate and mometasone furoate, in terms of patient preferences and sensory attributes 4.
- Research has also evaluated the systemic bioactivity of Nasacort and other intranasal corticosteroids, finding no significant differences in markers of systemic bioactivity compared to baseline values or between different treatments 5.
Efficacy and Safety
- Intranasal corticosteroids like Nasacort are considered safe and effective for the treatment of allergic rhinitis, with minimal systemic adverse effects 2, 3.
- The most common adverse reactions associated with Nasacort and other intranasal corticosteroids are limited to the nasal mucosa, such as dryness, burning, and stinging, as well as headache and epistaxis in some patients 3.
- Studies have shown that Nasacort and other intranasal corticosteroids can provide significant relief from symptoms of allergic rhinitis, including nasal congestion, itching, and sneezing 2, 3, 6.
Patient Preferences and Compliance
- Patient preferences for intranasal corticosteroids like Nasacort can affect adherence to treatment, with some studies suggesting that patients prefer Nasacort due to its sensory attributes, such as less odor and taste 4.
- Expected compliance with Nasacort and other intranasal corticosteroids can also vary depending on patient preferences and the specific product attributes 4.